Evidence map›Paper›PMID 33401658›Full record

ReviewMolecules (Basel, Switzerland)2021

Progress in the Application of Nanoparticles and Graphene as Drug Carriers and on the Diagnosis of Brain Infections.

Mahmood Barani, Mahwash Mukhtar, Abbas Rahdar, Ghasem Sargazi, Anna Thysiadou, George Z Kyzas

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Synergistic antibacterial mechanism of silver-copper bimetallic nanoparticles.Frontiers in bioengineering and biotechnology · 2023
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Mahmood BaraniDepartment of Chemistry, Shahid Bahonar University of Kerman, Kerman 76169-14111, Iran.ORCID 0000-0002-1711-2522
Mahwash MukhtarFaculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0001-8447-2950
Abbas RahdarDepartment of Physics, Faculty of Science, University of Zabol, Zabol 538-98615, Iran.ORCID 0000-0003-4766-9214
Ghasem SargaziNoncommunicable Diseases Research Center, Bam University of Medical Science, Bam 5166-15731, Iran.ORCID 0000-0001-7340-0943
Anna ThysiadouDepartment of Chemistry, International Hellenic University, 65404 Kavala, Greece.
George Z KyzasDepartment of Chemistry, International Hellenic University, 65404 Kavala, Greece.ORCID 0000-0003-1516-3761
International Hellenic University · GRBam University of Medical Sciences · IRShahid Bahonar University of Kerman · IRUniversity of Szeged · HUZabol University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The blood-brain barrier (BBB) is the protective sheath around the brain that protects the sensitive microenvironments of the brain. However, certain pathogens, viruses, and bacteria disrupt the endothelial barrier and cause infection and hence inflammation in meninges. Macromolecular therapeutics are unable to cross the tight junctions, thereby limiting their bioavailability in the brain. Recently, nanotechnology has brought a revolution in the field of drug delivery in brain infections. The nanostructures have high targeting accuracy and specificity to the receptors in the case of active targeting, which have made them the ideal cargoes to permeate across the BBB. In addition, nanomaterials with biomimetic functions have been introduced to efficiently cross the BBB to be engulfed by the pathogens. This review focuses on the nanotechnology-based drug delivery approaches for exploration in brain infections, including meningitis. Viruses, bacteria, fungi, or, rarely, protozoa or parasites may be the cause of brain infections. Moreover, inflammation of the meninges, called meningitis, is presently diagnosed using laboratory and imaging tests. Despite attempts to improve diagnostic instruments for brain infections and meningitis, due to its complicated and multidimensional nature and lack of successful diagnosis, meningitis appears almost untreatable. Potential for overcoming the difficulties and limitations related to conventional diagnostics has been shown by nanoparticles (NPs). Nanomedicine now offers new methods and perspectives to improve our knowledge of meningitis and can potentially give meningitis patients new hope. Here, we review traditional diagnosis tools and key nanoparticles (Au-NPs, graphene, carbon nanotubes (CNTs), QDs, etc.) for early diagnosis of brain infections and meningitis.

Indexed as

Brain DiseasesDrug CarriersDrug Delivery SystemsGraphiteHumansMeningitisNanomedicineNanoparticlesNanotechnologyDrug CarriersGraphitebraindiagnosismeningitisnanomaterialstreatment

Identifiers

PMID33401658
PMCPMC7795866
OpenAlexW3117876478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.